Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
ANAB
ANAB
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
ANAB News
Anaptysbio Biotech Stock Breaks Trendline
Feb 03 2026
Yahoo Finance
AnaptysBio Director Sells 3,900 Shares for $193,342.50
Jan 12 2026
NASDAQ.COM
AnaptysBio Director Sells 3,900 Shares for $193,342.50
Jan 12 2026
Fool
AnaptysBio CMO Paul Lizzul Sells 3,650 Shares for $163,191.50
Jan 11 2026
NASDAQ.COM
AnaptysBio CMO Sells 3,650 Shares for $163,191.50
Jan 11 2026
Fool
AnaptysBio Fights Tesaro Lawsuit, Seeks to Uphold Licensing Rights
Jan 09 2026
Benzinga
AnaptysBio Moves to Dismiss Tesaro's Breach Claim Ahead of July 2026 Trial
Jan 08 2026
Globenewswire
ALX Oncology Gains 10.17% on Positive Phase 2 Trial Data for Evorpacept
Jan 08 2026
NASDAQ.COM
AnaptysBio CEO Daniel Faga to Present at J.P. Morgan Healthcare Conference on January 13, 2026
Jan 06 2026
Globenewswire
Vanda Submits BLA for Imsidolimab to Treat GPP
Dec 15 2025
PRnewswire
Wedbush Affirms Outperform Rating for AnaptysBio, Keeps $50 Price Target Intact
Nov 24 2025
Benzinga
Midday Stock Highlights: Notable Movements from Oracle, Bath & Body Works, Gap, and Others
Nov 21 2025
CNBC
GSK's Tesaro Files Lawsuit Against AnaptysBio, Endangering Jemperli Royalties for Cancer Treatment
Nov 21 2025
Benzinga
Premarket Stock Highlights: Notable Moves in Bitcoin Stocks, Elastic, Gap, and Others
Nov 21 2025
CNBC
Major Stocks Including Elastic, Veeva Systems, and HIVE Digital Decline in Friday's Pre-Market Trading
Nov 21 2025
Benzinga
GSK and AnaptysBio File Lawsuits Against Each Other Regarding Cancer Drug License
Nov 21 2025
WSJ
Show More News
